Patient information, communication and competence empowerment in oncology

Not Applicable

• Conditions: C00-C97; D45; D46; D47; D48; Malignant neoplasms; Polycythaemia vera; Myelodysplastic syndromes; Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue; Neoplasm of uncertain or unknown behaviour of other and unspecified sites

• Registration Number: DRKS00016703
• Lead Sponsor: IKK Südwest

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-02-21
• Study Completion: 2021-02-28
• Results First Posted: 2023-05-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1004

Inclusion Criteria

Diagnosis of diagnosis groups C00-C97 or D45-D48; initial diagnosis, relapse and transition to palliative care; treatment by doctors from the Saarland; insured with one of the health insurances participating in this study

Exclusion Criteria

statutory guardianship; insufficient knowledge of the German language; very strong visual and hearing impairment; dementia; mental limitations

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Health-related quality of life (SF-12), measured by pre-intervention questionnaires plus 3 and 6 months after baseline

Secondary Outcome Measures

Name	Time	Method
Self-efficacy (SWE), depression (PHQ9), anxiety (GAD7), health literacy (HLS-EU-47), treatment satisfaction (Qualiskope-A): measured with pre-intervention questionnaires plus 3 and 6 months after baseline.<br>Furthermore, direct medical costs (days of inability to work, sick-pay, ambulant and hospital treatment, medication costs, use of psychotherapeutic treatments) are identified from secondary data analysis from health insurances.